神経変性疾患治療市場レポート：適応症別、薬剤タイプ別、投与経路別、流通チャネル別、地域別、2025～2033年

世界の神経変性疾患治療市場規模は2024年に783億米ドルに達しました。今後、IMARC Groupは、同市場が2033年までに1,185億米ドルに達し、2025～2033年の成長率（CAGR）は4.48%になると予測しています。

神経変性疾患とは、中枢神経系（CNS）または末梢神経系（PNS）のニューロンの構造と機能が進行性に変性する脳疾患群を指します。現在、身体的あるいは精神的症状を軽減し、患者の生活の質を向上させるために、いくつかの薬剤が利用可能です。さらに研究者は、神経変性疾患を早期に発見・診断し、その進行を予防するための分子診断法、特にバイオマーカーや画像分光法の開発に注力しています。

過度のアルコール摂取に起因する腫瘍や脳卒中の有病率の増加は、高齢者人口の増加と相まって、神経変性疾患の発症リスクを高める主要な要因の一つとなっています。このことは、アルツハイマー病、パーキンソン病、ハンチントン病、筋萎縮性側索硬化症などの神経変性疾患の早期診断のための分子診断技術の必要性をさらに高めています。これとは別に、研究者たちはこれらの疾患の分類を効果的に理解するために、神経病理学的手法と分子生物学的手法を組み合わせています。また、さまざまなタイプの神経変性疾患に対する低侵襲（MI）スクリーニング検査の開発も進められています。さらに，神経変性疾患の危険因子についての認識を高めるために，非政府組織（NGO）とともに，多くの国の行政機関がさまざまな健康教育キャンペーンを支援しています。インフラの改善によるヘルスケア施設へのアクセスの増加や可処分所得の増加といったその他の要因も、今後数年間の市場の成長を促進すると予想されます。

本レポートで扱う主な質問

• 世界の神経変性疾患治療市場はこれまでどのように推移し、今後どのように推移するのか？
• COVID-19が世界の神経変性疾患治療市場に与えた影響は？
• 主要な地域市場とは？
• 適応症別の市場内訳は？
• 薬剤タイプ別の市場内訳は？
• 投与経路別の市場内訳は？
• 販売チャネル別の市場内訳は？
• 業界のバリューチェーンにおける様々な段階とは？
• 業界の主な促進要因と課題は何か？
• 世界の神経変性疾患治療市場の構造と主要企業は？
• 業界における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の神経変性疾患治療市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：適応症別

• 多発性硬化症
• パーキンソン病
• アルツハイマー病
• 脊髄性筋萎縮症（SMA）
• ハンチントン病
• その他

第7章 市場内訳：薬剤タイプ別

• N-メチル-D-アスパラギン酸受容体拮抗薬
• 選択的セロトニン再取り込み阻害薬
• ドーパミン阻害剤
• その他

第8章 市場内訳：投与経路別

• 経口
• 注射剤
• その他

第9章 市場内訳：流通チャネル別

• 病院薬局
• 小売薬局
• その他

第10章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Biogen
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A

List of Figures

• Figure 1: Global: Neurodegenerative Disease Treatment Market: Major Drivers and Challenges
• Figure 2: Global: Neurodegenerative Disease Treatment Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 4: Global: Neurodegenerative Disease Treatment Market: Breakup by Indication (in %), 2024
• Figure 5: Global: Neurodegenerative Disease Treatment Market: Breakup by Drug Type (in %), 2024
• Figure 6: Global: Neurodegenerative Disease Treatment Market: Breakup by Route of Administration (in %), 2024
• Figure 7: Global: Neurodegenerative Disease Treatment Market: Breakup by Distribution Channel (in %), 2024
• Figure 8: Global: Neurodegenerative Disease Treatment Market: Breakup by Region (in %), 2024
• Figure 9: Global: Neurodegenerative Disease Treatment (Multiple Sclerosis) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 10: Global: Neurodegenerative Disease Treatment (Multiple Sclerosis) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 11: Global: Neurodegenerative Disease Treatment (Parkinson's Disease) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 12: Global: Neurodegenerative Disease Treatment (Parkinson's Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 13: Global: Neurodegenerative Disease Treatment (Alzheimer's Disease) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 14: Global: Neurodegenerative Disease Treatment (Alzheimer's Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 15: Global: Neurodegenerative Disease Treatment (Spinal Muscular Atrophy- SMA) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 16: Global: Neurodegenerative Disease Treatment (Spinal Muscular Atrophy- SMA) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 17: Global: Neurodegenerative Disease Treatment (Huntington's Disease) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 18: Global: Neurodegenerative Disease Treatment (Huntington's Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 19: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 20: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 21: Global: Neurodegenerative Disease Treatment (N-methyl-D-aspartate Receptor Antagonists) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 22: Global: Neurodegenerative Disease Treatment (N-methyl-D-aspartate Receptor Antagonists) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 23: Global: Neurodegenerative Disease Treatment (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 24: Global: Neurodegenerative Disease Treatment (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 25: Global: Neurodegenerative Disease Treatment (Dopamine Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 26: Global: Neurodegenerative Disease Treatment (Dopamine Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 27: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 28: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 29: Global: Neurodegenerative Disease Treatment (Oral) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 30: Global: Neurodegenerative Disease Treatment (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 31: Global: Neurodegenerative Disease Treatment (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 32: Global: Neurodegenerative Disease Treatment (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 33: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 34: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 35: Global: Neurodegenerative Disease Treatment (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 36: Global: Neurodegenerative Disease Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 37: Global: Neurodegenerative Disease Treatment (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 38: Global: Neurodegenerative Disease Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 39: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 40: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 41: North America: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 42: North America: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 43: United States: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 44: United States: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 45: Canada: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 46: Canada: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 47: Asia-Pacific: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 48: Asia-Pacific: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 49: China: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 50: China: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 51: Japan: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 52: Japan: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 53: India: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 54: India: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 55: South Korea: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 56: South Korea: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 57: Australia: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 58: Australia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 59: Indonesia: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 60: Indonesia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 61: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 62: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 63: Europe: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 64: Europe: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 65: Germany: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 66: Germany: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 67: France: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 68: France: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 69: United Kingdom: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 70: United Kingdom: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 71: Italy: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 72: Italy: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 73: Spain: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 74: Spain: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 75: Russia: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 76: Russia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 77: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 78: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 79: Latin America: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 80: Latin America: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 81: Brazil: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 82: Brazil: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 83: Mexico: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 84: Mexico: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 85: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 86: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 87: Middle East and Africa: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
• Figure 88: Middle East and Africa: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 89: Middle East and Africa: Neurodegenerative Disease Treatment Market: Breakup by Country (in %), 2024
• Figure 90: Global: Neurodegenerative Disease Treatment Industry: SWOT Analysis
• Figure 91: Global: Neurodegenerative Disease Treatment Industry: Value Chain Analysis
• Figure 92: Global: Neurodegenerative Disease Treatment Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Neurodegenerative Disease Treatment Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Indication (in Million USD), 2025-2033
• Table 3: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
• Table 4: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
• Table 5: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
• Table 6: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 7: Global: Neurodegenerative Disease Treatment Market: Competitive Structure
• Table 8: Global: Neurodegenerative Disease Treatment Market: Key Players

The global neurodegenerative disease treatment market size reached USD 78.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 118.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4.48% during 2025-2033.

Neurodegenerative diseases refer to a group of brain disorders that lead to progressive degeneration of the structure and function of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). Presently, several medications are available to reduce physical or mental symptoms and improve the quality of patients' life. Moreover, researchers are focusing on developing molecular diagnostics, especially biomarkers and imaging spectroscopy, to detect and diagnose neurodegenerative diseases at an early stage and prevent their progression.

The growing prevalence of tumors and stroke on account of excessive alcohol consumption, in confluence with the rising geriatric population, represents one of the major factors increasing the risk of developing neurodegenerative diseases. This is further escalating the need for molecular diagnostic techniques for early diagnosis of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Apart from this, researchers are combining neuropathological methods with molecular biology techniques to understand the classification of these diseases effectively. They are also developing minimally invasive (MI) screening tests for different types of neurodegenerative diseases. Furthermore, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of neurodegenerative diseases. Other factors, such as increasing access to healthcare facilities on account of improving infrastructure and inflating disposable incomes, are anticipated to drive the growth of the market in the coming years.

Key Market Segmentation:

Breakup by Indication:

• Multiple Sclerosis
• Parkinson's Disease
• Alzheimer's Disease
• Spinal Muscular Atrophy (SMA)
• Huntington's Disease
• Others

Breakup by Drug Type:

• N-methyl-D-aspartate Receptor Antagonists
• Selective Serotonin Reuptake Inhibitors
• Dopamine Inhibitors
• Others

Breakup by Route of Administration:

• Oral
• Injectable
• Others

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Biogen, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and UCB S.A.

Key Questions Answered in This Report:

• How has the global neurodegenerative disease treatment market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global neurodegenerative disease treatment market?
• What are the key regional markets?
• What is the breakup of the market based on the indication?
• What is the breakup of the market based on the drug type?
• What is the breakup of the market based on the route of administration?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global neurodegenerative disease treatment market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Neurodegenerative Disease Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Indication

• 6.1 Multiple Sclerosis
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Parkinson's Disease
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Alzheimer's Disease
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Spinal Muscular Atrophy (SMA)
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Huntington's Disease
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Others
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Drug Type

• 7.1 N-methyl-D-aspartate Receptor Antagonists
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Selective Serotonin Reuptake Inhibitors
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Dopamine Inhibitors
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

• 8.1 Oral
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Injectable
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Hospital Pharmacies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Retail Pharmacies
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Biogen
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Boehringer Ingelheim International GmbH
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 F. Hoffmann-La Roche AG
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
  • 15.3.4 GlaxoSmithKline Plc
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 SWOT Analysis
  • 15.3.5 Merck & Co. Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Novartis AG
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Pfizer Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Sanofi S.A
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Teva Pharmaceutical Industries Ltd.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 UCB S.A
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis